Mesoblast Limited Stock price Nasdaq

Equities

MESO

US5907174016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 10:13:42 2024-03-28 am EDT 5-day change 1st Jan Change
4.09 USD +17.19% Intraday chart for Mesoblast Limited +80.48% +85.40%
Sales 2024 * 11.59M 7.54M Sales 2025 * 14.73M 9.58M Capitalization 633M 412M
Net income 2024 * -105M -68.33M Net income 2025 * -118M -76.79M EV / Sales 2024 * 59.4 x
Net Debt 2024 * 55.05M 35.82M Net Debt 2025 * 93.28M 60.7M EV / Sales 2025 * 49.3 x
P/E ratio 2024 *
-4.34 x
P/E ratio 2025 *
-4.74 x
Employees 83
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.03%
More Fundamentals * Assessed data
Dynamic Chart
1 day+20.06%
1 week+92.26%
Current month+120.56%
1 month+107.89%
3 months+101.16%
6 months+73.80%
Current year+97.50%
More quotes
1 week
2.05
Extreme 2.05
4.96
1 month
1.91
Extreme 1.9098
4.96
Current year
1.61
Extreme 1.61
4.96
1 year
1.61
Extreme 1.61
10.24
3 years
1.61
Extreme 1.61
18.22
5 years
1.61
Extreme 1.61
42.56
10 years
1.61
Extreme 1.61
54.02
More quotes
Managers TitleAgeSince
Founder 67 04-06-07
Director of Finance/CFO - 12-05-31
Chief Operating Officer 60 20-07-23
Members of the board TitleAgeSince
Chief Tech/Sci/R&D Officer 73 13-04-14
Chairman 72 18-06-17
Director/Board Member 76 14-03-05
More insiders
Date Price Change Volume
24-03-28 4.075 +16.76% 3 414 104
24-03-27 3.49 -11.20% 5,025,574
24-03-26 3.93 +78.64% 69,182,352
24-03-25 2.2 +1.85% 282,299
24-03-22 2.16 -4.42% 177,424

Delayed Quote Nasdaq, March 28, 2024 at 09:35 am EDT

More quotes
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.495 AUD
Average target price
0.69 AUD
Spread / Average Target
+39.39%
Consensus
  1. Stock
  2. Equities
  3. Stock Mesoblast Limited
  4. Stock Mesoblast Limited - Nasdaq